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A B S T R A C T
Local chemotherapy with carmustine-impregnated wafers showed safe and eﬀective in the treatment of ma-
lignant glioma, with infrequent, though sometime serious, adverse eﬀects.
We report a rare case of cerebral vasospasm following glioblastoma removal with carmustine wafers im-
plantation in a 57-years-old man. After surgery, the patient awoke with aphasia, due to vasospasm of the left
middle cerebral artery. Intra-arterial infusion of nimodipine was performed, with rapid vasospasm resolution
and quick recovery.
Cerebral vasospasm is an extremely rare adverse eﬀect after carmustine wafers implantation in glioma sur-
gery, with only one case reported. In our case, intra-arterial nimodipine was rapidly eﬀective. Although rare,
such a potentially disastrous complication should be considered when a new neurological deﬁcit unexpectedly
occurs after carmustine wafers implantation, and vascular investigation should be undertaken.
1. Introduction
For the last ten years, local chemotherapy with carmustine-im-
pregnated wafers (Gliadel®, Eisai Inc., Woodcliﬀ Lake, NJ, USA) in the
treatment of malignant glioma has demonstrated an improvement of
median overall survival with acceptable safety proﬁle [1–3].
Carmustine wafer, which is designed to release biodegradable 1,3-
bis-2-chloroethyl-1-nitrosurea (BCNU), has the advantages of bypassing
the blood-brain barrier, delivering BCNU directly to peritumoral tissue,
and avoiding systemic toxicity [4,5]. Carmustine wafers are placed
along the wall of the surgical site, and the chemotherapeutic agent is
released continuously, diﬀusing into the parenchyma over approxi-
mately 3–8weeks, with peak release in the ﬁrst 2 weeks [5]. However,
several adverse events have been associated with Gliadel® implanta-
tion, the most common of which include seizures, brain edema, and
intracranial hypertension [3]. Other uncommon adverse events are
reported in the literature, including wound healing defects, intracranial
infections, cerebral hemorrhage, cerebrospinal ﬂuid leakage, hydro-
cephalus, and cyst formation [1,2,4,6]. According to the current lit-
erature, only one case of carmustine wafer-related vasospasm with
cerebral infarction has been described [7].
We report a case of symptomatic vasospasm after implantation of
carmustine wafers in a patient treated for left frontotemporal glio-
blastoma (GBM).
2. Case report
A 57-year-old man was admitted to ER for sudden onset of confu-
sion, amnesia and insomnia. Magnetic resonance imaging (MRI) re-
vealed a mass located in the left temporal lobe and insula with perile-
sional edema, showing inhomogeneous ring enhancement (Fig. 1).
The patient was referred to our department and underwent surgery
for tumor resection via left frontotemporal craniotomy. The resection
was extended to the deep area of the frontal lobe and the insula, which
appeared inﬁltrated. Sylvian arteries were preserved, except some small
branches supplying the tumor. We obtained CT-conﬁrmed subtotal re-
section (> 95%) of the tumor (Fig. 2a). Eight carmustine wafers were
placed on the wall of the resection cavity and secured with Tabotamp
strips.
Histopathological examination revealed typical ﬁndings of WHO
grade IV glioma. On postoperative day one, once sedation was inter-
rupted and patient awoke, he showed moderate aphasia, with no other
neurological deﬁcit. CT and CT-angiography (CTA) were performed and
revealed persistence of brain edema around the surgical cave, without
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postoperative bleeding (Fig. 2a). However, vasospasm was shown at the
M2 segments of the left middle cerebral artery and M3 insular branches
(Fig. 2b), which was conﬁrmed by digital subtraction angiography
(DSA) (Fig. 3a). In the same session, 5mg nimodipine were infused in
30min in the left internal carotid artery through a 5F catheter [8], with
increased size of M2 and better visualization of insular branches
(Fig. 3b). Oral nimodipine (60mg 6 times daily) was continued for
7 days and then tapered oﬀ. Aphasia resolved in two days. Transcranial
Doppler monitoring showed vasospasm disappearance after 72 h. The
patient was discharged on the 18th postoperative day and underwent
radiotherapy and temozolomide chemotherapy. At last follow-up,
15 months after operation, he is free of symptoms and tumor recurrence
on MRI (Fig. 4).
3. Discussion
Implantation of carmustine-impregnated wafers (Gliadel®) has de-
monstrated a survival beneﬁt in patients with malignant glioma [1–3].
However, a number of adverse reactions have been commonly reported
[1–4,6], while vasospasm was described in only one case report before
[7].
The present case is, at our knowledge, the second reported case of
symptomatic cerebral vasospasm associated with carmustine wafers
implantation, conﬁrming vasospasm as a possible rare side eﬀect. The
mechanism of vasospasm induced by Gliadel® remains unclear, al-
though the vasoactive eﬀect of carmustine has been already described
in diﬀerent situations. Shingleton et al. [9] reported that high-dose
intravenous carmustine (800mg/m2) has been associated with retinal
artery narrowing and obstruction. With carmustine wafers the local
concentration at the implantation site is 1200 times higher than con-
centration achieved by systemic administration [5]. Possibly, local
toxicity of carmustine or foreign body reaction to the wafer material
may trigger local inﬂammatory response leading to vasospasm [7].
More speciﬁcally, in a rabbit lung model, BCNU inhibited glutathione
reductase activity, resulting in increase of induced vasospasm, due to
hydrogen-peroxide-induced prostanoid formation and calcium shift
[10].
Vasospasm and cerebral infarction are rare complications of brain
tumor surgery in general. In a large series of 470 skull base tumors, the
incidence of vasospasm was 1.9% only [11]. In a systematic review of
cerebral vasospasm following tumor resection,< 50 cases were found,
and most of them were benign lesions [12], while only one case related
to GBM is reported [13]. These data reinforce the hypothesis that, in
our case, local carmustine may have played a causative role. In fact,
Fig. 1. Preoperative contrast-enhanced MRI. Axial (a) and coronal (b) images, compatible with high grade glioma.
Fig. 2. Postoperative CT. a) Contrast-enhanced image showing normal postoperative ﬁndings, with carmustine wafers lying on the wall of surgical cavity, and small
enhancing remains in the posterior lateral border; b) CT-angiography revealed vasospasm of the left middle cerebral artery (M2-M3 branches).
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while intraoperative mechanical arterial manipulation is perhaps one of
the most important surgical factors for vasospasm, it is mainly con-
sidered for skull base tumor surgery [11]. Increased tumor vascularity
with blood spillage into the cisternal space has also been advocated as a
cause of vasospasm [12]. However, in our patient there was no post-
operative hemorrhage. Moreover, while vasospasm after tumor resec-
tion is usually delayed several days after surgery [7,11–13], in our case
it occurred< 24 h after operation, thus suggesting a direct vasoactive
eﬀect on the vessels.
In the previously reported case [7], vasospasm and cerebral in-
farction appeared 12 days after surgery, while in our case neurological
impairment and vasospasm occurred the day after operation. A possible
explanation of this diﬀerence is that, in our case, the sylvian vessels had
been exposed and were close to wafers, whereas in the other case len-
ticulostriate arteries were covered by some residual tumor. Therefore,
carmustine might have taken a longer time to reach the vessels by
diﬀusing through the intervening tissue. Moreover, in our patient,
prompt and aggressive endovascular treatment of vasospasm prevented
eventual cerebral infarction, leading to complete neurological recovery
and good outcome.
4. Conclusions
We described a unique case of symptomatic vasospasm associated
with implantation of carmustine-impregnated wafers in the treatment
of GBM. Our aim is to contribute to the experience of using Gliadel®, by
remarking the importance of an uncommon but harmful adverse drug
reaction like vasospasm. Based on our experience, in case of sudden
onset of new focal neurological deﬁcit after carmustine wafers im-
plantation, with “normal” CT scan, vasospasm should be suspected and
vascular investigation prompted. In our case, intra-arterial infusion of
nimodipine, followed by oral administration, led to rapid reversal of
vasospasm and full neurological recovery.
The patient has consented to submission of this case report to the
journal.
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